NCT03871322

Brief Summary

a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC), investigating the effect of vitamin K2 (menaquinone-7) and vitamin D3 on the healing process of low-energy bone fractures in children and adolescents

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 7, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 12, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 24, 2022

Completed
27 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2023

Completed
Last Updated

March 10, 2021

Status Verified

March 1, 2021

Enrollment Period

3.5 years

First QC Date

March 7, 2019

Last Update Submit

March 8, 2021

Conditions

Keywords

vitamin Dvitamin K2low-energy fracturesfracture healingchildren

Outcome Measures

Primary Outcomes (1)

  • time to bone union

    The bone fracture healing milestones will be based on bone union defined as the absence of pain and the presence of bridging callus in three of the four cortices seen on the AnteroPosteral and lateral radiographs

    3 months

Secondary Outcomes (3)

  • Vitamin D concentration changes

    3 months

  • Vitamin K2 concentration changes

    3 months

  • Changes in bone markers concentration

    3 months

Study Arms (3)

Vitamin D group

ACTIVE COMPARATOR

vitamin D supplementation - time to fracture healing

Dietary Supplement: Vitamin D supplementation

Vitamin D and K2 group

ACTIVE COMPARATOR

Vitamin D and K 2 supplementation - time of fracture healing

Dietary Supplement: Vitamin D and K2 supplementation

Placebo group

PLACEBO COMPARATOR

Placebo - time to fracture healing

Dietary Supplement: Placebo

Interventions

if supplementation of vitamin D and K2 changes the time to fracture healing

Vitamin D and K2 group
Vitamin D supplementationDIETARY_SUPPLEMENT

if supplementation of vitamin D alone changes the time to fracture healing

Vitamin D group
PlaceboDIETARY_SUPPLEMENT

Placebo control group

Placebo group

Eligibility Criteria

Age3 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age \< 18 years
  • Presence of low-energy fracture
  • Vitamin D serum level \<30ng/ml

You may not qualify if:

  • Age \> 18 years
  • Lack of low-energy bone fracture
  • Oral anticoagulants treatments, which interfere with vitamin K cycle
  • Current supplementation with vitamin vitamins K2 or vitamin D3
  • Osteogenesis imperfecta and other bone diseases
  • Vitamin D concentration \> 30ng/ml

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Pediatric Orthopedics and Traumatology Medical University of Bialystok

Bialystok, 15-274, Poland

RECRUITING

MeSH Terms

Interventions

Vitamin D

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Janusz Popko, MD, PhD

    Faculty of Health Sciences

    STUDY CHAIR
  • Michał Karpinski, MD

    Department of Pediatric Orthopedics and Traumatology

    PRINCIPAL INVESTIGATOR
  • Tomasz Guszczyn, MD, PhD

    Department of Pediatric Orthopedics and Traumatology

    STUDY CHAIR
  • Sylwia Chojnowska, PhD

    Faculty of Health Sciences Lomza

    STUDY CHAIR
  • Katarzyna Maresz, PhD

    International Science &amp;Health Foundation

    STUDY CHAIR
  • Vladimir Badmaev

    American Medical Holdings Inc

    STUDY DIRECTOR

Central Study Contacts

Michał Karpiński, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
double-blind, placebo, same looking capsules
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC),
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2019

First Posted

March 12, 2019

Study Start

July 1, 2019

Primary Completion

December 24, 2022

Study Completion

January 20, 2023

Last Updated

March 10, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations